Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024 : vimarsana.com

WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to provide shareholders with an update on recent progress in the development of BeaMed’s groundbreaking StingRay Laser System (the “System”). BeaMed is a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovat

Related Keywords

Israel , United States , Gil Shapira , Moshe Eshkol , Leo Ehrlich , Israel Institute Of Technology , Exchange Commission , Innovation Pharmaceuticals Inc , Rambam Health Care Campus , Massachusetts Institute Of Technology , Newmediawire Innovation Pharmaceuticals , Innovation Pharmaceuticals , Med Technologies , Stingray Laser System , Beamed System , Technion Israel Institute , Rambam Health Care , Key Opinion Leaders , Chief Executive Officer , Stingray System , Massachusetts Institute , Looking Statements , Private Securities Litigation Reform Act , Pharmaceuticals , T Beamed Technologies , He Company , Ompany , Roduct Development , Aser System , Iopharmaceutical Company , Linical Indications , Ystem , Linical Stage ,